Tr
Yep that was what a lot of SRX shareholders were probably thinking when it it's SP dropped from $30 to $15. However it is now $13 an looks like a far more attractive option with an established product in the liver cancer salvage market with no debt and $100m in it's account that makes profit and currently buying back it's shares. Again DYOR but I know which horse I prefer to bet on!
Add to My Watchlist
What is My Watchlist?